Passage BIO Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| · · · · · · · · · · · · · · · · | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · | ||||||||||
| · · Common stock · · Additional · · · Accumulated other · · · Accumulated · · · | ||||||||||
| (in thousands, except share data) | Shares | Amount | paid‑in capital | | | comprehensive income (loss) | | deficit | | Total |
| Balance at January 1, 2025 | 62,061,774 | | $6 | $720,482 | | $8 | | $(659,235) | | $61,261 |
| Exercise of stock options and vesting of restricted stock units | 86,500 | | — | — | | — | | — | | — |
| Unrealized gain (loss) on marketable securities | — | | — | — | | (8) | | — | | (8) |
| Share‑based compensation expense | — | | — | 858 | | — | | — | | 858 |
| Net loss | — | | — | — | | — | | (15,405) | | (15,405) |
| Balance at March 31, 2025 | 62,148,274 | | $6 | $721,340 | | $— | | $(674,640) | | $46,706 |
Statements of Stockholders’ Equity
| | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| · · Common stock · · Additional · · · Accumulated other · · · Accumulated · · · | ||||||||||||||||
| (in thousands, except share data) · Shares · · Amount · · paid‑in capital · · · comprehensive income (loss) · · deficit · · Total | ||||||||||||||||
| Balance at January 1, 2024 | 54,944,130 | | $5 | $705,789 | | $(43) | | $(594,468) | | $111,283 | ||||||
| Issuance of common stock under the ATM Facility, net of offering costs | | 6,000,000 | | | 1 | | 8,741 | | | — | | | — | | | 8,742 |
| Exercise of stock options and vesting of restricted stock units | | 667,666 | | | — | | — | | | — | | | — | | | — |
| Unrealized gain (loss) on marketable securities | | — | | | — | — | | | (26) | | | — | | | (26) | |
| Share‑based compensation expense | — | | | — | | 1,595 | | | — | | | — | | | 1,595 | |
| Net loss | — | | | — | | — | | | — | | | (16,711) | | | (16,711) | |
| Balance at March 31, 2024 | 61,611,796 | | $6 | $716,125 | | $(69) | | $(611,179) | | $104,883 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.